Still, further optimization, mechanistic exploration and chronic in vivo evaluation are needed to determine its potential for clinical application and to establish whether dual SGLT1/2-modulating NAH derivatives can represent a viable, safe and effective strategy within the expanding spectrum of precision therapies for metabolic diseases. This evidence concerns the gene SLC5A1 and Other metabolic disease.